[go: up one dir, main page]

WO2020041447A1 - Aiguille hypodermique jetable à auto-mélange - Google Patents

Aiguille hypodermique jetable à auto-mélange Download PDF

Info

Publication number
WO2020041447A1
WO2020041447A1 PCT/US2019/047472 US2019047472W WO2020041447A1 WO 2020041447 A1 WO2020041447 A1 WO 2020041447A1 US 2019047472 W US2019047472 W US 2019047472W WO 2020041447 A1 WO2020041447 A1 WO 2020041447A1
Authority
WO
WIPO (PCT)
Prior art keywords
needle
cartridge
reservoir
admixing
syringe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/047472
Other languages
English (en)
Inventor
William E. Pounds
Jason STREETER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurim LLC
Original Assignee
Aurim LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurim LLC filed Critical Aurim LLC
Priority to CA3110434A priority Critical patent/CA3110434A1/fr
Publication of WO2020041447A1 publication Critical patent/WO2020041447A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A61M5/284—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle comprising means for injection of two or more media, e.g. by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A61M5/285—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle with sealing means to be broken or opened
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3202—Devices for protection of the needle before use, e.g. caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/34—Constructions for connecting the needle, e.g. to syringe nozzle or needle hub
    • A61M5/347—Constructions for connecting the needle, e.g. to syringe nozzle or needle hub rotatable, e.g. bayonet or screw
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/60—General characteristics of the apparatus with identification means
    • A61M2205/6063—Optical identification systems
    • A61M2205/6072—Bar codes

Definitions

  • the present invention is directed to syringes and, more particularly, to a self-admixing disposable hypodermic needle and process for dental, medical, and other admixing purposes.
  • the central nervous system is responsible for processing sensory information relayed by sensory neurons called receptor cells, neural pathways, and parts of the brain involved in sensory perception.
  • Senses are transducers from the physical world to the mind, via the central nervous system, where we interpret the information, creating our perception of the world around us.
  • anesthesia there are two basic types of anesthesia in use. The first is a general anesthesia which causes a full loss of consciousness thereby adding serious risk to the patient. The second is a temporarily induced and fully reversable local anesthesia which has significantly less risk to the patient facilitated by parenteral placement via hypodermic needle of a local anesthetic like Lidocaine® to suppress the pain sensing and signal transduction pathway to the brain via nerves near the procedure site alleviating the pain.
  • a local anesthetic like Lidocaine®
  • the pH of the local anesthetic can be adjusted to be closer to the patient’s body pH of 7.4 to facilitate a shorter onset time of anesthesia and more pronounced anesthetic effect which is beneficial to the patient. This also increases the efficiency of the dentist, or medical practitioner by reducing the time required to complete the painful procedure.
  • the invention may be embodied in a self-admixing disposable hypodermic needle (also referred to as an“admixing needle” for descriptive convenience) and a procedure for its use to hypodermically inject a combined injection mixture, such as buffered Lidocaine, into a patient for the purposes of local anesthesia.
  • the admixing needle includes a reservoir containing a predetermined amount of an additive (e.g., a buffering agent) to be mixed with an injection fluid (e.g., Lidocaine) to create a combined injection mixture to be injected from a cartridge by a syringe, such as an aspirating syringe.
  • an additive e.g., a buffering agent
  • an injection fluid e.g., Lidocaine
  • the admixing needle is attached to the syringe, which holds the injection fluid cartridge, with the cartridge needle extending into the cartridge.
  • a delivery needle cap is then pushed toward the syringe to push a reservoir plunger into the reservoir to force the additive out of the reservoir, through the cartridge needle, and into the cartridge.
  • This dispenses the additive from the reservoir of the admixing needle into the cartridge to create an injection mixture within the cartridge.
  • the thumb ring is then used to push the syringe plunger towards the admixing needle to force the injection mixture from the cartridge back through the admixing needle and into the patient.
  • Mixing surfaces on the reservoir plunger and reservoir homogeneously combine the injection fluid from the cartridge with the additive from the admixing needle as they pass back through, and out of, the admixing needle and hypodermically into the patient.
  • FIG. 1 is a side view of a delivery needle on a admixing needle.
  • FIG. 2 is a side view of a cartridge needle on the admixing needle.
  • FIGS. 3A-3C include a side view and both orthogonal end views of a male body (reservoir plunger) on the admixing needle.
  • FIGS. 4A-4C include a side view with two sectional interior views and both orthogonal end views of a female body (reservoir) on the admixing needle.
  • FIGS. 5A-5C include a side view and both orthogonal end views of a delivery needle cap on the admixing needle.
  • FIGS. 6A-6C include a side view and both orthogonal end views of a cartridge needle cap on the admixing needle.
  • FIG. 7 is a conceptual illustration of an identification label and sterility seal on the admixing needle.
  • FIG. 8 is a sectional side view of the admixing needle in the“as shipped” (pre-use) condition.
  • FIG. 9 is a sectional side view of the admixing needle with the delivery needle cap removed in the process of being attached to a syringe.
  • FIG. 10 is a sectional side view of the admixing needle fully attached to the syringe and with the male body (reservoir plunger) partially pushed into the female body (reservoir).
  • FIG. 1 1 is a sectional side view of the admixing needle fully attached to the syringe with the male body (reservoir plunger) linearly translated into the female body (reservoir) to a position just before latching and fluid bypass groove valve operation whereby only allowing fluid to flow from the admixing needle to the injection fluid cartridge.
  • FIG. 12 is a sectional side view of the admixing needle fully attached to the syringe with the male body (reservoir plunger) latched into the female body (reservoir) which positions these two components to activate the fluid bypass groove valve enabling bi-directional fluid flow which allows the injection mixture (in this example Lidocaine buffered with sodium bicarbonate) to be excised from the cartridge located within the syringe anteriorly through the delivery needle on the admixing needle.
  • the injection mixture in this example Lidocaine buffered with sodium bicarbonate
  • FIG. 13 is a sectional side view of the admixing needle fully attached to the syringe with the injection mixture partially injected from the syringe through the admixing needle.
  • FIG. 14 is a sectional side view of the admixing needle attached to the syringe with the delivery needle cap replaced after use.
  • FIG. 15 is a sectional side view of the admixing needle detached from the syringe with the cartridge needle cap replaced and ready for disposal.
  • FIG. 16 is an exploded isometric view of the admixing needle showing its individual components.
  • FIG. 17 is an isometric view of the syringe with the admixing needle and injection fluid cartridges shown displaced.
  • FIGS. 18A-18B depict a logic flow diagram of a procedure for using the syringe and Injection fluid cartridge, in conjunction with the admixing needle.
  • the present invention may be embodied in a self-admixing disposable hypodermic needle (also referred to as an“admixing needle” for descriptive convenience) and related process for homogeneous admixing of two or more constituents into a final preparation on demand capable of combining two or more liquids or gasses or a liquid and a powder together upon their expulsion from the admixing needle to buffer or mix the final preparation just prior to administering, obviating the issues associated with pre- buffering or mixing too far in advance of the procedure or use.
  • the admixing needle is operated in a manner that is very similar to the standard hypodermic needles commonly employed today with only a single additional step that takes less than one second to accomplish.
  • the onset time of the local anesthetic prevents the dentist or medical practitioner from performing procedures that would cause the patient pain until the local anesthesia effect is complete as the receptor nerves or signal pathways are still functioning normally and the patient would feel it. This causes a wide variety of delays from one patient to another.
  • the buffered anesthetic solution facilitates higher lipid solubility allowing it to pass readily through the sensory nerve cell wall and makes the anesthetic more potent by increasing its effectiveness so that a lesser amount may be used to get a more profound and longer-lasting anesthesia effect.
  • the process of induced local anesthesia begins with the hypodermic placement of the local anesthetic parenterally in proximity of the nerve intended to be blocked near the proposed procedure site via a syringe, such as an aspirating syringe, through a admixing needle that intentionally inhibits the transmit or receive function of the local sensory nerves’ signaling ability along metabolic pathways in response to pain or other noxious stimuli during normal cellular biochemical cascade eliminating the pain response to the patient which allows the painful procedure to be completed sooner because of the buffered preparation’s reduced onset time or latency.
  • a syringe such as an aspirating syringe
  • the admixing needle can be used to administer local anesthetics which are membrane-stabilizing pharmaceuticals that reversibly decrease the rate of depolarization of excitable membranes (like nociceptors) and prevent them from reacting to external stimuli.
  • local anesthetics which are membrane-stabilizing pharmaceuticals that reversibly decrease the rate of depolarization of excitable membranes (like nociceptors) and prevent them from reacting to external stimuli.
  • These receptors are located at the cytoplasmic (inner) portion of the sodium channel.
  • a local anesthetic like Lidocaine works by moving to the inside of a nerve cell and then binding to the sodium channel and in doing so blocks the influx of sodium ions which prevents nerve conduction thus prohibits further pain signals from reaching the brain
  • any dental or medical procedure involving the hypodermic injection of local anesthetic can be responsible for some amount of patient pain and anxiety.
  • the main benefits of the admixing needle are the buffering of the local anesthetic preparation on demand (just prior to injection) to prevent the patient from experiencing pain sooner and more completely, which in turn reduces the patient’s anxiety.
  • the admixing needle also produces an increased and more pronounced anesthetic effect with longer lasting duration using less pharmaceutical to get the same benefit.
  • the C02 generated as a byproduct of the pH buffering processes’ chemical reaction can also potentiate the nerve impulse-blocking action on peripheral nerves.
  • Embodiments of the present invention will not require a significant deviation from the processes that are currently employed to hypodermically deliver a dose of local anesthetic to the patient or any change to the aspirating syringes and anesthetic cartridges already used as it is designed to replace only the disposable hypodermic needle normally attached to the aspirating syringe by substituting the admixing needle capable of buffering the anesthetic preparation.
  • Lidocaine with 1 : 100,000 epinephrine.
  • Lidocaine is a weak base that can precipitate in water over time.
  • hydrochloric acid strong acid
  • sodium hydroxide strong base
  • Lidocaine with epinephrine is approximately 1 ,000 times more acidic than subcutaneous tissue.
  • the anesthetic solution is H20, 2% Lidocaine hydrochloride by weight, 0.002% epinephrine by weight, and trace amounts of sodium hydroxide and/or hydrochloric acid, citric acid, and sodium metabisulfite.
  • Lidocaine molecules Due to the low pH of the anesthetic solution, the majority of Lidocaine molecules are attached to positive hydrogen ions. These ionized Lidocaine molecules cannot pass through the hydrophobic lipid bilayer of the nerve axon. The body must naturally buffer the anesthetic to a pH of around 7.4 before it can enter the sensory nerve and take effect. This buffering is accomplished by natural bicarbonate ions in the bloodstream produced as a biproduct of C02 during respiration.
  • the amount of basic, non-ionized Lidocaine is increased 6000 times. This form is able to cross the lipid bilayer of the sensory nerve axon readily. However, in order to block the sodium channels of the nerve and inhibit signal transduction, the Lidocaine must become ionized again with the addition of a H+ cation. Carbon dioxide is produced as a biproduct of the buffering operation chemical reaction. [0045] This increased concentration of carbon dioxide can readily cross the axon membrane where it facilitates the reverse reaction with the end product of ionized Lidocaine. Thus, carbon dioxide greatly enhances the anesthetic effect of the Lidocaine. Carbon dioxide also potentiates the action of local anesthetics by the direct depressant effect of C02 on the sensory nerve axon and by concentrating local anesthetic inside the nerve trunk via diffusion trapping.
  • the cell membrane also known as the plasma membrane or cytoplasmic membrane, is a biological membrane that separates the interior of all cells from the outside environment (the extracellular space). It consists of a lipid bilayer with embedded proteins.
  • the basic function of the cell membrane is to protect the cell from its surroundings.
  • the cell s membrane controls the movement of substances in and out of the cell. In this way, it is selectively permeable to ions and organic molecules and most receptive to the passage of ones of the correct pH. This is a crucial fact relating to the usefulness of the present invention
  • the sensory nerve cell with the local anesthetic applied will be in equilibrium with the formation of the pronated (ionized) form which does not readily pass back out of the cell and is referred to as ion trapping.
  • the molecule binds to the local anesthetic binding site on the inside of the ion channel near the cytoplasmic end.
  • the drug must penetrate the cell membrane which is achieved best in the non-ionized form and at the same pH as the human body.
  • a biochemical cascade (signaling cascade or signaling pathway) is a series of chemical pathways which are initiated by stimuli.
  • a nociceptor is a sensory neuron that responds to damaging or potentially damaging stimuli by sending“possible threat” signals to the brain via the spinal cord. If the brain thinks the threat is credible, it creates the sensation of pain to direct attention to the body part, so the threat can hopefully be mediated.
  • a nerve is an enclosed, cable-like bundle of axon (nerve) fibers and make up the long and slender projections of neurons in the peripheral nervous system.
  • a nerve provides a common pathway for the electrochemical nerve impulses that are transmitted along each of the axons to peripheral organs and the brain. These processes take place in the presence of stimuli.
  • neurons also known as a nerve cells
  • neurons are electrically excitable cells that receive, process, and transmit information through electrical and chemical signals.
  • the factors that influence the membrane potential are diverse. They include numerous types of ion channels, some of which are chemically gated and some of which are voltage gated. Because voltage-gated ion channels are controlled by the membrane potential, while the membrane potential itself is influenced by these same ion channels, feedback loops that allow for complex temporal dynamics arise, including oscillations and regenerative events such as action potentials.
  • Transduction proteins form or connect to miniscule pathways called ion channels through which charged particles called ions, like sodium or potassium, enter the cell. This movement of the charged particles creates the electrical signals. Each electrical signal spreads along the length of the cell by means of other proteins which also form ion channels ultimately culminating in the release of a chemical neurotransmitter. The next neuron receives the neurotransmitter via other receptor proteins, which also are themselves ion channels or coupled to, ion channels.
  • Ion channels provide passageways through which ions can move.
  • an ion channel is permeable only to specific types of ions (for example, sodium and potassium but not chloride or calcium), and sometimes the permeability varies depending on the direction of ion movement.
  • Ion pumps also known as ion transporters or carrier proteins, actively transport specific types of ions from one side of the membrane to the other, sometimes using energy derived from metabolic processes to do so.
  • Ligand-gated ion channels are channels whose permeability is greatly increased when some type of chemical ligand at the correct pH binds to the protein structure.
  • an action potential travels down an axon
  • sodium- (Na+) and potassium- (K+) gated ion channels open and close as the membrane reaches its threshold potential.
  • Na+ channels open at the beginning of the action potential, and Na+ moves into the axon, causing depolarization.
  • Repolarization occurs when the K+ channels open and K+ moves out of the axon, creating a change in polarity between the outside of the cell and the inside.
  • the impulse travels down the axon in one direction only, to the axon terminal where it signals other neurons.
  • Transmembrane proteins can also serve as ligand transport proteins that alter the permeability of the cell’s lipid bilayer membrane to small molecules and ions.
  • the membrane alone has a hydrophobic core through which polar or charged molecules cannot diffuse.
  • Membrane proteins contain internal channels that allow such molecules to enter and exit the cell. Many ion channel properties are specialized to select for only a particular ion; for example, potassium and sodium channels often discriminate for only one of the two ions.
  • Most ligands are soluble molecules from the extracellular medium which bind to cell surface receptors.
  • Ion pumps are integral membrane proteins that carry out active transport, i.e. , use cellular energy to“pump” the ions against their concentration gradient. Such pumps take in ions from one side of the membrane (decreasing the concentration there) and release them on the other side (increasing their concentration there).
  • the ion pump most relevant to the action potential is the sodium-potassium pump which transports three sodium ions out of the cell and two potassium ions in.
  • the concentration of potassium ions K+ inside the neuron is roughly 20- fold larger than the outside concentration, whereas the sodium concentration outside is roughly nine-fold larger than inside.
  • other ions have different concentrations inside and outside the neuron, such as calcium chloride and magnesium.
  • the sodium-potassium pump would be electrically neutral, but, because of the three-for-two exchange, it gives a net movement of one positive charge from intracellular to extracellular for each cycle, thereby contributing to a positive voltage difference.
  • the pump has three effects: (1 ) it makes the sodium concentration high in the extracellular space and low in the intracellular space; (2) it makes the potassium concentration high in the intracellular space and low in the extracellular space; (3) it gives the intracellular space a negative voltage with respect to the extracellular space.
  • the sodium-potassium pump is relatively slow in operation. If a cell were initialized with equal concentrations of sodium and potassium everywhere, it would take hours for the pump to establish equilibrium. The pump operates constantly but becomes progressively less efficient as the concentrations of sodium and potassium available for pumping are reduced.
  • Ion pumps influence the action potential only by establishing the relative ratio of intracellular and extracellular ion concentrations.
  • the action potential involves mainly the opening and closing of ion channels not ion pumps.
  • ion pumps play no significant role in the repolarization of the membrane after an action potential.
  • channels are specific (selective) for one ion; for example, most potassium channels are characterized by 1000:1 selectivity ratio for potassium over sodium, though potassium and sodium ions have the same charge and differ only slightly in their radius.
  • the channel pore is typically so small that ions must pass through it in single-file order.
  • Channel pores can be either open or closed for ion passage, although several channels demonstrate various sub-conductance levels.
  • ions permeate through the channel pore down the transmembrane concentration gradient for that particular ion.
  • the rate of ionic flow through the channel i.e. single-channel current amplitude, is determined by the maximum channel conductance and electrochemical driving force for that ion, which is the difference between the instantaneous value of the membrane potential and the value of the reversal potential.
  • a channel may have several different states (corresponding to different conformations of the protein), but each such state is either open or closed.
  • closed states correspond either to a contraction of the pore— making it impassable to the ion— or to a separate part of the protein, stoppering the pore.
  • the voltage- dependent sodium channel undergoes inactivation, in which a portion of the protein swings into the pore, sealing it. This inactivation shuts off the sodium current and plays a critical role in the action potential.
  • Ion channels can be classified by how they respond to their environment. For example, the ion channels involved in the action potential are voltage-sensitive channels; they open and close in response to the voltage across the membrane. Ligand- gated channels form another important class; these ion channels open and close in response to the binding of a ligand molecule, such as a neurotransmitter. Other ion channels open and close with mechanical forces. Still other ion channels such as those of sensory neurons open and close in response to other stimuli, such as light, temperature or pressure.
  • an action potential occurs when the membrane potential of a specific axon location rapidly rises and falls. This depolarization then causes adjacent locations to similarly depolarize. Action potentials occur in several types of cells, called excitable cells, which include neurons.
  • Action potentials are generated by special types of voltage-gated ion channels embedded in a cell's plasma membrane. These channels are shut when the membrane potential is near the (negative) resting potential of the cell, but they rapidly begin to open if the membrane increases to a precisely defined threshold voltage, depolarizing the transmembrane potential. When the channels open, they allow an inward flow of sodium ions, which changes the electrochemical gradient, which in turn produces a further rise in the membrane potential. This then causes more channels to open, producing a greater electric current across the cell membrane, and so on. The process proceeds explosively until all the available ion channels are open, resulting in a large upswing in the membrane potential.
  • the cell membrane or plasma membrane, is a biological membrane that surrounds the cytoplasm of the cell wall. The membrane separates and protects the cell from its surrounding environment. It is mostly made up of a double layer of phospholipids, which are amphiphilic, partly hydrophobic and partly hydrophilic. It is also called a fluid mosaic membrane. Embedded within this membrane is a variety of protein molecules acting as channels and pumps that move various molecules in and out of the cell.
  • the intermediate space is located between the outer and inner membrane. It is also called the pepmitochondial space and is freely permeable to small molecules.
  • concentration of small molecules, such as ions and sugars, is the same as in the cytosol or intracellular fluid also known as the cytoplasmic matrix.
  • Extracellular fluid denotes body fluid outside of cells. Extracellular fluid provides the medium for the exchange of substances between the extracellular fluid and the cells. This normally takes place by dissolving, mixing, and transporting in the fluid medium. This is where the local anesthetic is deposited hypodermically via the admixing needle injection and a crucial fact related to the usefulness of the invention.
  • Voltage-gated ion channels in the cell membrane can be temporarily opened under specific circumstances to allow a brief inflow of sodium ions into the cell. This is due to the sodium ion concentration gradient that exists between the outside and the inside of the cell, which causes the cell to temporarily depolarize (lose its electrical charge) forming the basis of action potentials.
  • Lidocaine is one local anesthetic that binds preferentially to the inactive state of the voltage-gated sodium channels but has also been found to bind to potassium channels, G-protein coupled receptors, NMDA receptors, and calcium channels which are all part of the nerve signal transmission process within the central nervous system.
  • Ion pumps are the proteins that build and maintain the chemical gradients by utilizing an external energy source to move ions against the concentration gradient to an area of higher chemical potential. Alternatively, the energy source can be another chemical gradient already in place. It is through the action of ion pumps that cells are able to regulate pH via the pumping of protons.
  • ion channels In contrast to ion pumps, ion channels do not build chemical gradients but rather dissipate them in order to perform work or send a signal. Probably the most familiar and best studied example is the voltage-gated Na+ channel, which allows conduction of an action potential along neurons. All ion pumps have some sort of trigger or“gating” mechanism. In the previous example it was electrical bias, but other channels can be activated by binding a molecular agonist or through a conformational change in another nearby protein.
  • Ligands are termed first messengers, while receptors are the signal transducers which then activate primary effectors. Such effectors are often linked to second messengers, which can activate secondary effectors, and so on.
  • First messengers are signaling molecules that reach the cell from extracellular fluid and bind to specific receptors.
  • Second messengers are substances that enter the cytoplasm and act within the cell to trigger a response. As an electrical signal reaches a threshold voltage level and so propagates along its length, the cell opens sodium channels to allow the influx of sodium ions. These sodium channels are proteins (poly-amino acids) that sit across the membrane that forms the surface of the nerve. This protein folds into a cylindrical shape with a central channel that can be the nerve cell. [0085] Most signal transduction pathways involve the binding of signaling molecules (ligands) to receptors that trigger events inside of the cell. Activation energy is the minimum energy required to start a chain reaction.
  • Extracellular receptors are integral transmembrane proteins and make up the greater percentage of these receptors. They span the plasma membrane of the cell, with one part of the receptor on the outside and one on the inside. Ligands bind to the part which is outside the cell which induces a change in the configuration of the inside part. This is called receptor activation. This either results in the activation of an enzyme domain of the receptor or the exposure of the binding site for other intracellular signaling proteins within the cell, eventually propagating the signal through the cytoplasm.
  • the lipid bilayer (or phospholipid bilayer) is a thin polar membrane made of two layers of lipid molecules. These membranes are flat sheets that form a continuous barrier around all cells.
  • the cell membranes of almost all living organisms and many viruses are made of a lipid bilayer, as are the membranes surrounding the cell nucleus and other sub-cellular structures.
  • the lipid bilayer is the barrier that keeps ions, proteins and other molecules where they are needed and prevents them from diffusing into areas where they should not be.
  • Lipid bilayers are ideally suited to this role, even though they are only a few nanometers in width, they are impermeable to most water-soluble (hydrophilic) molecules. Bilayers are particularly impermeable to ions, which allows cells to regulate salt concentrations and pH by transporting ions across their membranes using proteins called ion pumps.
  • Lipid bilayers are also involved in signal transduction through their role as the home of integral membrane proteins.
  • Lipid kinases phosphorylate lipids in the cell, both on the plasma membrane as well as on the membranes of the organelles.
  • the addition of phosphate groups can change the reactivity and localization of the lipid and can be used in signal transmission.
  • Some local anesthetic preparations also contain a vasoconstrictor like epinephrine to control bleeding and prolong the anesthetic effect by reducing blood-flow to and from the area which is responsible for the body’s normal expulsion of the preparation which ends the local anesthetic effect and usefulness. Buffering the solution will have no deleterious effect on these preparations or to the patient. The buffered solution will be removed during the body’s normal excretion process which is responsible to remove xenobiotics (foreign molecules) thereby ending the local anesthesia event albeit much more slowly.
  • a vasoconstrictor like epinephrine
  • the admixing needle is practical for dental or medical local anesthetic preparation buffering but not limited to such uses and could also involve point of use mixing of gels, liquids, or gasses or chemically activated epoxies or glues that would set up or harden if mixed together too far in advance.
  • the admixing needle 1000 which includes a delivery needle 100, cartridge needle 200, male body (reservoir plunger) 300, female body (reservoir) 400, delivery needle cap 500, cartridge needle cap 600, and an identification label and sterility seal 700, as shown in FIG. 16.
  • the reservoir contains a predetermined volume of an 8.4% solution of sodium bicarbonate neutralizing (buffering) solution or other admixing constituent to facilitate homogeneous mixing when conjoined with a syringe.
  • the syringe is an aspirating syringe 800, which concentrically predisposes and maintains the mechanical position of an injection fluid cartridge 900, as shown in Fig. 17.
  • the injection fluid cartridge 900 contains the local anesthetic Lidocaine
  • the reservoir 400 of the admixing needle 1000 contains sodium bicarbonate to buffer (alkalize) the Lidocaine by mixing the two liquids together.
  • the mixing initially occurs by forcing the additive in the female body (reservoir) 400 into the injection fluid cartridge 900 to create an injection mixture within the injection fluid cartridge 900. Additional mixing occurs when the syringe is operated to force the injection mixture from the injection fluid cartridge 900 back out through the admixing needle 1000, which homogeneously mixes the injection fluid with the additive immediately prior to delivery to the patient via hypodermic injection.
  • the process begins with the dentist or medical practitioner inserting the injection fluid injection fluid cartridge 900 into the cartridge port 802 of the syringe 900, as shown in FIG. 17, with the cartridge diaphragm 902 and the cartridge metal diaphragm clamp 903 facing the anterior end of the syringe 800.
  • the practitioner retracts the syringe plunger 805 by placing their thumb into the syringe thumb ring 804 and, while gripping the syringe finger grip 807 on the anterior side of the syringe finger bar 808, moving the syringe plunger 805 posteriorly to create a bit of space between the cartridge 900 and the harpoon barb 806, which is predisposed on the end of the syringe plunger 805.
  • the posterior end of the syringe thumb ring 804 is then sharply struck with the palm to set the harpoon barb 806 into the cartridge stopper 901 , which is predisposed at the posterior end of the injection fluid cartridge glass body 904.
  • the previous steps of the local anesthetic injection procedure are identical to the currently followed procedure.
  • the correct length and gage of the admixing needle 1000 is selected for the intended injection required by reviewing the identification label and sterility seal 700, which is located across the cartridge needle cap label area 602, and the delivery needle cap label area 502, as shown in FIG. 16, which incorporates human and/or machine readable identification label markings 701.
  • the label 700 also includes an Identification label base color 702, identification label colored stripe 704, and held on with identification label sterility adhesive 703, as shown in FIG. 7.
  • the cartridge needle cap 600 as shown in FIG.
  • the female body (reservoir) 400 incorporates a female body cartridge needle receiver 402, as shown in FIG. 4, into which is embedded a cartridge needle blunt end 203, on a cartridge needle 200, containing a cartridge needle lumen 204, which is a hollow pathway for fluid to bidirectionally flow as shown in FIG. 2, and secured to the female body (reservoir) 400 with female body needle adhesive 410.
  • the cartridge needle bevel point end 201 located on the posterior end of the admixing needle 1000, is coaxially aligned with a needle access lumen 809 of the syringe 800 which receives the cartridge needle 200.
  • the admixing needle 1000 is attached to the syringe 800 by placing the female body chamfered lead-in 409, and female body female threaded area 408, over the syringe male threaded area 801 , and rotating the admixing needle 1000 clockwise to tighten, as shown in FIG. 17, by gripping it by the delivery needle cap external spline 505.
  • the female body external female groove 406 is a longitudinally displaced feature that accepts the delivery needle cap internal spline 501 , which is a longitudinally displaced feature which only allows the delivery needle cap 500, to move longitudinally relative to the female body (reservoir) 400, and directly transfer the clockwise radial tightening force. This ensures ingress of the cartridge needle bevel point 201 into the injection fluid cartridge diaphragm 902, which is made of an elastomeric material that seals around the exterior periphery of the cartridge needle body 202.
  • the male body first seal ring 302 which is a thin, circular, male feature on the male body (reservoir plunger) 300, interacts with the internal surface of the female body cavity 401 , which is smooth, to create a piston effect by deflecting slightly anteriorly to maintain proper contact pressure with the inside diameter.
  • Varying the dimensions of these component parts will allow for different volumes of additives as well as the prepositioning of the male body (reservoir plunger) 300 within the female body (reservoir) 400.
  • the delivery needle cap 500 is then moved posteriorly towards the syringe 800, along the female body external female groove 406 and the female body external male spline 407, thereby engaging the delivery needle cap internal conical area 503 with the male body tapered nose 306, which transfers the liner force and posteriorly translates the male body (reservoir plunger) 300 toward and into the female body (reservoir) 400.
  • male body second seal ring 303 which is a thin, circular, male feature on the male body (reservoir plunger) 300, interacts with the female body end ring snap lock 405, on the female body (reservoir) 400, an audible and tactile“click” indication is given to the dentist or medical practitioner.
  • male body third seal ring 304 which is a thin, circular, male feature on the male body (reservoir plunger) 300, interacts with the female body end ring snap lock Indicator 405, on the female body (reservoir) 400, an audible and tactile“click” indication is given to the dentist or medical practitioner and the male body insertion stop surface 308, comes into contact with the anterior end of the female body (reservoir) 400, to stop the ingress of the male body (reservoir plunger) 300, into the female body cavity 401 , which also irreversibly locks the two together.
  • the male body first seal ring 302 passes through the female body fluid bypass groove 404, which is an undercut feature on the inside wall of the female body cavity 401 on the female body (reservoir) 400. This provides a fluid ingress and egress path between the injection fluid cartridge 900, and the male body needle receiver 301 , in which the delivery needle blunt end 103 is affixed with the male body needle adhesive 309.
  • the syringe thumb ring 804 is moved posteriorly to determine if the delivery needle bevel point 101 is positioned within a vein or artery by looking through the syringe cartridge port 802, or the syringe view port 803, to see if blood has been withdrawn into the reservoir area 905 of the injection fluid cartridge 900, which would be visible through the cartridge glass body 904.
  • This withdrawing action creates a negative pressure area (vacuum) within the cartridge reservoir area 905, which also brings any residual vestige of the additive solution left in the female body cavity 401 , or the cartridge needle lumen 204, into the injection fluid cartridge 900.
  • the dentist or medical practitioner then moves the syringe thumb ring 804 anteriorly towards the injection fluid cartridge 900, which in turn moves the cartridge stopper 901 anteriorly thus decreasing the volume within the injection fluid cartridge 900. This, in turn, increases the pressure on the injection mixture forcing it out the only egress path available, which is the cartridge needle lumen 204.
  • This lumen is in axial communication with a mixing surface of the female body, in this example the mixing rings 403, until it interacts with a mixing surface of the male body, in this example the mixing rings 305, which are geometric features of both male (reservoir plunger) and female (reservoir) parts that direct and redirect the flow of the preparation in a radially and outwardly direction across them which creates vortices and turbulence responsible to effect the homogeneous mixing.
  • the preparation also moves around the male body first seal ring 302, passes through the female body fluid bypass groove 404, and down through the male body intersecting fluid pathway 307, which has fluid communication with the male body needle receiver 301 , in which the delivery needle blunt end 103, is affixed with male body needle adhesive 309, which coaxially aligns the delivery needle body 102, having a delivery needle lumen 104, and a delivery needle bevel point 101 , which finally interacts with the patient.
  • the delivery needle 100 is removed from the patient and, if additional local anesthetic placement is required and there is still some injection mixture (in this example buffered Lidocaine) left in the cartridge, the delivery needle can be repositioned within the stratified squamous epithelium tissues to the proximity of a different nerve repeating the aspiration step to test for mispositioning within the venous or arterial system.
  • additional local anesthetic placement is required and there is still some injection mixture (in this example buffered Lidocaine) left in the cartridge, the delivery needle can be repositioned within the stratified squamous epithelium tissues to the proximity of a different nerve repeating the aspiration step to test for mispositioning within the venous or arterial system.
  • the balance or required amount of the injection mixture can be administered.
  • the delivery needle cap 500 is replaced over the delivery needle 100 to prevent accidental contaminated needle sticks.
  • the admixing needle 1000 can then be removed from the syringe male threads 801 by rotating the delivery needle cap 500 counterclockwise to unseat it.
  • the cartridge needle 200 can then be covered with the cartridge needle cap 600 and the admixing needle properly discarded.
  • the used injection fluid cartridge 900 is removed from the syringe 800 and disposed of properly. If additional injection mixture is needed to completely facilitate the local anesthesia effect necessary to permit the painful procedure, the entire procedure is repeated as many times as is required up to the maximum legal dosage.
  • FIGS. 18A-18B depict a logic flow diagram 1800 of a procedure for using the aspirating syringe 800 and the injection fluid cartridge 900 in conjunction with the admixing needle 1000.
  • the injection fluid is Lidocaine
  • the additive is sodium bicarbonate
  • resulting buffered Lidocaine as the injection mixture.
  • the procedure can be performed by a syringe user, such as dentist, physician, veterinarian, technician, medical practitioner, and so forth.
  • the admixing needle 1000 is specifically designed for use with the aspirating syringe 800 by a dental or medical professional, it may find use in other settings in which the admixing needle 1000 is used with an aspirating syringe or other suitable type of syringe by humans or machines.
  • step 1801 the user grasps the aspirating syringe 800 and retracts the syringe plunger 805 of the aspirating syringe 800 and inserts a cartridge containing an injection fluid, in this example a Lidocaine cartridge 900, into the cartridge port 802 of the aspirating syringe 800. See Fig. 17.
  • a cartridge containing an injection fluid in this example a Lidocaine cartridge 900
  • Step 1801 is followed by step 1802, in which the user grasps the aspirating syringe 800 with one hand and sharply strikes the posterior end of the thumb ring 804 on the aspirating syringe 800, which seats the syringe harpoon barb 806 located on the anterior end of the syringe plunger 805 into the posterior end of the Lidocaine cartridge stopper 901 located at the posterior end of the Lidocaine cartridge 900. See Fig. 12.
  • Step 1802 is followed by step 1803, in which the user rotates the cartridge needle cap 600 with respect to the delivery needle cap 500, and pulls the cartridge needle cap 600 linearly away from the delivery needle cap 500 to break the identification label and sterility seal 700 and removes the cartridge needle cap 600. See Fig. 8.
  • Step 1803 is followed by step 1804, in which the user inserts the cartridge needle 200 into the Lidocaine cartridge 900 through the needle access lumen 809 and screws the female threaded area 408 of the female body (reservoir) 400 of the admixing needle 1000 onto the male threaded area 801 of aspirating syringe 800 fully. See Fig. 9 and 10.
  • Step 1804 is followed by step 1805, in which the user pushes the delivery needle cap 500 posteriorly towards the aspirating syringe 800 to linearly translate the male body (reservoir plunger) 300 into the female body (reservoir) 400 to begin to excise the buffering agent into Lidocaine cartridge 900. See Fig. 10 and 11.
  • Step 1805 is followed by step 1806, in which the user firmly pushes the delivery needle cap 500 further towards the aspirating syringe 800 until the user hears and feels a tactile click indicating that the buffering agent has been fully excised into the Lidocaine cartridge 900, at which point the male body (reservoir plunger) 300 is irreversibly latched into female body (reservoir) 400 to create a mixing area between the male body mixing rings 305 on the male body first seal ring 302 and the female body mixing rings 403 on the inside the female body cavity 401.
  • the admixing needle 1000 can only be used once (single-use) for admixing but, after single-use operation, the admixing needle may still be used as a non-admixing hypodermic needle for the aspirating syringe 800 or another suitable syringe.
  • the user may shake the aspirating syringe 800 to aid mixing the additive (in this example the buffering agent) with the injection fluid (in the example Lidocaine) within the cartridge 900. This mechanical action helps speed the chemical mixing of the constituents. See Fig. 12.
  • Step 1806 is followed by step 1807, in which the user rotates the delivery needle cap 500 as far clockwise as possible to align a delivery needle internal male spline with 501 on the inside of the delivery needle cap 500 with a longitudinal groove 406 in the female body (reservoir) 400 and removes the delivery needle cap 500 from the admixing needle 1000. See Fig. 12.
  • Step 1807 is followed by step 1808, in which the user places the admixing needle 1000 hypodermically into the patient’s squamous stratified epithelium tissues and pulls the syringe thumb ring 804 posteriorly to create a vacuum within the Lidocaine cartridge reservoir area 905 which in turn creates a vacuum through the entire admixing needle 1000 to the patient’s tissues. If the delivery needle 100 is improperly placed within the venous or arterial system of the patient it will bring blood back through the admixing needle 1000 and into the Lidocaine cartridge 900 which will be visible through the cartridge glass body 904 and the syringe cartridge port 802 or syringe view port 803.
  • the delivery needle 100 would be withdrawn some amount and or repositioned within the patient’s non-venous or non-arterial squamous stratified epithelium tissues.
  • Step 1808 is followed by step 1809, in which the user pushes the syringe thumb ring 804 of the aspirating syringe 800, which in turn linearly translates the syringe plunger 805 toward the admixing needle 1000 (operates syringe) to excise the injection mixture (in this example buffered Lidocaine) from the Lidocaine cartridge reservoir area 905 within the Lidocaine cartridge glass body 904. See Fig. 12.
  • Step 1809 is followed by step 1810, in which the injection mixture is forced between the mixing rings 305 of the male body (reservoir plunger) 300 and the female body mixing rings 403 inside the female body cavity 401, around the male body first seal ring 302 via the female body fluid bypass groove 404 which make up the valve, and out the delivery needle lumen 104 via the male body intersecting fluid pathway 307 to thoroughly mix the buffered Lidocaine upon delivery to the patient via the delivery needle 100. See Figs. 3A-3C.
  • Step 1810 is followed by step 1811 , in which the user withdraws the delivery needle 100 from the patient and replaces the delivery needle cap 500 over the delivery needle 100 and engages the internal spline 501 of the delivery needle cap 500 against the female body external groove 406 of the female body (reservoir) 400. See Fig.14.
  • Step 1811 is followed by step 1812, in which the user rotates the delivery needle cap 500 counterclockwise to unscrew the female body threaded area 408 of the female body (reservoir) 400 of the admixing needle 1000 from the syringe male threaded area 801 of aspirating syringe 800.
  • Step 1812 is followed by step 1813, in which the user replaces the cartridge needle cap 600 over the cartridge needle 200 and safely disposes of the admixing needle 1000. See Fig.15.
  • the illustrative procedure is dental anesthesia administration in which the injection fluid is Lidocaine and the additive is a buffering agent, such as sodium bicarbonate.
  • a buffering agent such as sodium bicarbonate.
  • embodiments of the invention may be used for a wide range of procedures and processes involving mixing of an admixing constituent with an injection fluid immediately before dispensing the combined mixture.
  • the embodiments of the invention may include a wide range of dental, medical, veterinarian, industrial and other procedures involving the dispensing of combined mixtures into human, animal, or inanimate subjects and/or objects.
  • the admixing needle may work with any type of syringe, and is well suited to working with the type of aspirating syringe commonly used to inject local a anesthetic into a dental patient.
  • the syringe may be operated by human or mechanical operators.
  • the injection fluid may be an anesthetic, medication, lubricant, or any other type of injection fluid suitable for dispensing using a syringe or mechanical means.
  • the buffering agent may be an acid neutralizer, admixture component, catalyst, dye, radioactive marker, or any other type of constituent to be added and mixed with an injection fluid immediately prior to delivery (dispensing) of the combined mixture.
  • embodiments of the invention include a method and apparatus, referred to as a self-admixing disposable hypodermic needle (also referred to as an “admixing needle” for descriptive convenience), for mixing two constituents into a homogeneous solution upon demand and dispensing from the admixing needle.
  • a self-admixing disposable hypodermic needle also referred to as an “admixing needle” for descriptive convenience
  • a representative embodiment of the admixing needle includes: a delivery needle; a cartridge needle; a male body (reservoir plunger); a female body (reservoir); a delivery needle cap; a cartridge needle cap; and an identification label and sterility seal.
  • the delivery needle includes: a bevel point; a body; a blunt end; and a lumen.
  • the cartridge needle includes: a bevel point; a body; a blunt end; and a lumen.
  • the male body (reservoir plunger) includes: a needle receiver; a first seal ring; a second seal ring; a third seal ring; mixing rings; a tapered nose; an intersecting fluid pathway; an insertion stop surface; and a needle adhesive.
  • the female body includes: a cavity; a cartridge needle receiver; mixing rings; a fluid bypass groove; an end ring snap lock; an external female groove; an external male spline; a female threaded area; a chamfered lead-in; and a needle adhesive.
  • the delivery needle cap includes: an internal spline; a label area; an internal conical area; a chamfer; an external spline and a syringe cap stop ring.
  • the cartridge needle cap includes: an external spline; a label area; an internal conical area; and a chamfer.
  • the identification label and sterility seal includes: markings; a base color; a sterility adhesive; and a colored stripe.
  • the aspirating syringe includes: a male threaded area; a cartridge port; a view port; a thumb ring; a syringe plunger; a harpoon barb; a finger grip; a finger bar; and a needle access lumen.
  • the injection fluid (in this example Lidocaine) cartridge includes: a stopper; a diaphragm; a metal diaphragm clamp; a glass body; and a reservoir area.
  • the process of creating a homogeneous mixture of two or more solutions into a final preparation upon demand facilitated by a admixing needle may including the steps of:
  • a cartridge apparatus e.g., Lidocaine or the like
  • the aspirating syringe assembly apparatus or the like having the ability to preferentially arrange and maintain the coaxial and linear positions of the admixing needle and the cartridge apparatus during the mixing process and during their kinetic mechanical interactions
  • the aspirating syringe assembly apparatus or the like having the ability to interact with, and manipulate the longitudinal position of the stopper of the cartridge apparatus during the mixing and delivery process
  • the posterior longitudinal motion of the cartridge stopper has the ability to increase the volume of the injection fluid cartridge reservoir area whereby decreasing the pressure on the solution within the reservoir
  • the anterior longitudinal motion of the stopper has the ability to decrease the volume of the Injection fluid cartridge reservoir area whereby increasing the pressure on the solution within the reservoir area
  • the pre-mixing of the at least two constituent fluids, powders, or gasses in the Lidocaine or other injection fluid cartridge being the result of the turbulence and vortices created by the at least one fluid being expelled from the posterior cartridge needle lumen at the cartridge needle bevel end at a higher pressure than the at least one fluid contained in the Injection fluid cartridge reservoir area and/or the cartridge stopper moving posteriorly,
  • At least two solutions may be homogeneously mixed to create one preparation just prior to hypodermically delivering them parenterally into the squamous stratified epithelium or the like near nerves that it is desirous to stop the signaling cascade of pain impulses to the brain to facilitate one or more dental or medical procedures which would normally cause an excess of noxious pain signals to the patient preventing the procedure or procedures.
  • a feature of the illustrative embodiments includes the ability to remove the Injection fluid cartridge after it is empty from the aspirating syringe while the admixing needle is still conjoined to the aspirating syringe to reload additional fully charged injection fluid cartridges for unmixed (unbuffered) use after the patient’s nerve signaling pathway has been substantially inhibited from previous buffered or unbuffered local anesthetic injections.
  • Another illustrative feature includes the mechanical position of the identification label and security seal spanning circumferentially and at least 360 degrees over the delivery needle cap label area and the cartridge needle cap label area to maintain the sterility of the internal areas including the fluid reservoir, delivery needle, and cartridge needle of the admixing needle.
  • Another illustrative feature includes the human-readable text, machine- readable bar code or two dimensional universal identification (2D UID) markings, and/or external color or laterally displaced color stripe on the outside of a said identification label and security seal to identify desirous features of the admixing needle not visible from the outside including but not limited to delivery needle length and or gage.
  • 2D UID two dimensional universal identification
  • Another illustrative feature includes the identification label sterility adhesive located on the opposite side of the identification label and security seal to the markings which secures it to the admixing needle delivery needle and cartridge needle caps.
  • Another illustrative feature includes the removal of only the cartridge needle cap from the admixing needle by applying rotational and posterior linear forces to the cartridge needle cap to disengage the sterility seal and identification label adhesive whereby permitting removal of the cartridge needle cap from the delivery needle cap.
  • Another illustrative feature includes the insertion of the cartridge needle bevel end into the aspirating syringe needle access lumen to align it coaxially with the cartridge diaphragm.
  • Another illustrative feature includes further travel of the cartridge needle bevel end into the aspirating cartridge needle access lumen whereby piercing the cartridge diaphragm with the admixing needle cartridge needle bevel end.
  • Another illustrative feature includes the mechanical position and interaction of the diaphragm seal on the injection fluid cartridge being made of an elastomericly compounded material and having the ability to allow the ingress of the cartridge needle bevel end via puncture during the mechanical interconnection of the admixing needle with the aspirating syringe.
  • Another illustrative feature includes the interaction of the cartridge needle of the admixing needle to the injection fluid cartridge to create a bidirectional fluid communication path which facilitates the at least one first solution contained within the admixing needle to transfer to the reservoir area of the injection fluid cartridge.
  • Another illustrative feature includes the interaction of the cartridge needle on the admixing needle to the injection fluid cartridge reservoir area create a fluid communication path which facilitates the transfer of the at least one second solution contained within the reservoir area of the injection fluid cartridge apparatus to the admixing needle.
  • Another illustrative feature includes the mechanical position and interaction of the diaphragm seal on the injection fluid cartridge being made of an elastomericly compounded material and having the ability to provide and maintain a pressure seal around the body of the cartridge needle during the mechanical interconnection of the admixing needle with the aspirating syringe assembly apparatus and during the entire mixing and admixed fluid delivery process.
  • Another illustrative feature includes an attachment method capable of conjoining the female body female threaded area on said admixing needle to the syringe male threaded area on the said aspirating syringe assembly apparatus like but not limited to a set of matched male and female screw threads.
  • Another illustrative feature includes the placement of the female body chamfered lead-in located on the female body of the admixing needle over the male threads on the aspirating syringe assembly apparatus until the female body female threads contact the male threads on the aspirating syringe assembly apparatus.
  • Another illustrative feature includes the interaction of the at least one longitudinally said delivery needle cap internal spline member with the at least one receiving said mentioned female body external female spline or groove member which allows longitudinal posterior motion while transferring the radial motion applied to the delivery needle cap to conjoin the admixing needle fully to the aspirating syringe assembly apparatus.
  • Another illustrative feature includes the placement of the injection fluid cartridge within an aspirating syringe apparatus with the ability to be conjoined to the admixing needle to allow mechanical interaction and bidirectional fluid flow between their fluid containing components.
  • Another illustrative feature includes the interaction of the harpoon barb which is attached to the syringe plunger, which is attached to the thumb ring all being components of the aspirating syringe wherein the harpoon barb anterior point pierces the posterior end of the cartridge stopper, being made of an elastomeric material, rubber or the like, due to a sharp force being anteriorly applied to the posterior end of the thumb ring whereby preventing the barb from being easily removed from the stopper during the posterior motion of the thumb ring and transferring the posterior linear force from the thumb bring to the stopper.
  • Another illustrative feature includes the injection fluid (e.g., Lidocaine) cartridge stopper, while being circumferentially engaged to the smooth inside circular surface of the injection fluid cartridge glass body which bounds the cartridge reservoir area’s volume in conjunction with the cartridge diaphragm, is able to travel longitudinally given an appropriate amount of anterior or posterior mechanical force transmitted through the harpoon barb, syringe plunger, and thumb ring being components of the aspirating syringe assembly apparatus provides linear motion of the cartridge stopper within the cartridge.
  • injection fluid e.g., Lidocaine
  • Another illustrative feature includes the conjoining of the harpoon barb to the cartridge stopper thereby transferring any posterior motion from the thumb ring to the cartridge stopper and reduce the pressure applied to the at least two fluids contained within the cartridge glass body by increasing the volumetric area containing the at least two fluids to create a vacuum.
  • Another illustrative feature includes the conjoining of the harpoon barb to the cartridge stopper thereby transferring any anterior motion from the thumb ring to the cartridge stopper and induce additional pressure to the at least two fluids contained within the cartridge reservoir area by reducing the volumetric area containing the at least two fluids.
  • Another illustrative feature includes the ability to replace the delivery needle cap over the admixing needle after completing one or more injections to protect the dentist or medical practitioner from accidental needle sticks.
  • Another illustrative feature includes the ability to replace the delivery needle cap over the admixing needle after completing one or more injections and to facilitate removal from the aspirating syringe for safe disposal. And another illustrative feature includes the ability to replace the cartridge needle cap over the admixing needle after completing one or more injections for safe disposal.
  • injection fluid e.g., Lidocaine®

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La présente invention concerne une aiguille hypodermique jetable à auto-mélange (aiguille de mélange) qui comprend un réservoir contenant un additif, tel qu'un agent tampon, pour faciliter le mélange homogène de l'additif avec un fluide d'injection, tel que la lidocaïne, contenu dans une cartouche maintenue à l'intérieur d'une seringue liée mécaniquement. L'aiguille de mélange établit une voie de communication fluidique pour administrer de manière hypodermique le mélange d'injection à un patient avant une intervention dentaire ou médicale potentiellement douloureuse. Avant le retrait, un capuchon d'aiguille d'administration est poussé vers la seringue pour distribuer l'additif dans la cartouche. L'aiguille d'administration est ensuite placée dans les tissus du patient et la seringue est actionnée pour expulser le mélange d'injection de la cartouche. Des surfaces de mélange sur le corps mâle (plongeur de réservoir) et le corps femelle (réservoir) et d'autres éléments mécaniques combinent de manière homogène le fluide d'injection à l'additif lorsque le mélange d'injection se déplace à travers l'aiguille de mélange pendant l'injection hypodermique.
PCT/US2019/047472 2018-08-22 2019-08-21 Aiguille hypodermique jetable à auto-mélange Ceased WO2020041447A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3110434A CA3110434A1 (fr) 2018-08-22 2019-08-21 Aiguille hypodermique jetable a auto-melange

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721479P 2018-08-22 2018-08-22
US62/721,479 2018-08-22

Publications (1)

Publication Number Publication Date
WO2020041447A1 true WO2020041447A1 (fr) 2020-02-27

Family

ID=69591061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/047472 Ceased WO2020041447A1 (fr) 2018-08-22 2019-08-21 Aiguille hypodermique jetable à auto-mélange

Country Status (2)

Country Link
CA (1) CA3110434A1 (fr)
WO (1) WO2020041447A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161195A (en) * 1963-01-29 1964-12-15 American Cyanamid Co Two-compartment aspirating hypodermic syringe
US5281198A (en) * 1992-05-04 1994-01-25 Habley Medical Technology Corporation Pharmaceutical component-mixing delivery assembly
WO2007101772A1 (fr) * 2006-03-07 2007-09-13 Novo Nordisk A/S Dispositif de melange de medicaments
US20150053305A1 (en) * 2013-08-20 2015-02-26 Infusion Medical, Inc. Syringe fill system and method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161195A (en) * 1963-01-29 1964-12-15 American Cyanamid Co Two-compartment aspirating hypodermic syringe
US5281198A (en) * 1992-05-04 1994-01-25 Habley Medical Technology Corporation Pharmaceutical component-mixing delivery assembly
WO2007101772A1 (fr) * 2006-03-07 2007-09-13 Novo Nordisk A/S Dispositif de melange de medicaments
US20150053305A1 (en) * 2013-08-20 2015-02-26 Infusion Medical, Inc. Syringe fill system and method

Also Published As

Publication number Publication date
CA3110434A1 (fr) 2020-02-27

Similar Documents

Publication Publication Date Title
US11839738B2 (en) Medication infusion device
US9579257B2 (en) Haptic feedback and audible output syringe
US5360410A (en) Safety syringe for mixing two-component medicaments
EP2569031B1 (fr) Injecteur précis de faible volume
EP0796118B1 (fr) Seringue
DE69807924T2 (de) Flüssigkeitsübertragungsvorrichtung verbindend einen medizinischen behälter und ein iv- beutel im geschlossenen system
US10420888B2 (en) Double-chamber mixing syringe and method of use
US20070100288A1 (en) Auto-injection devices and methods for intramuscular administration of medications
US20100145305A1 (en) Low volume accurate injector
EP2283885A1 (fr) Unité de dosage pour dispositif d'injection
US4413991A (en) Dual dose ampule
US20180256818A1 (en) Multi chamber syringe unit and method of preparing a multi chamber syringe
CN102448512A (zh) 用来容许在笔式注射器中的混合的固定部件和装置
CA2779206C (fr) Ensemble seringue-carpule
US20100106097A1 (en) Drug acceptability indicator
CN1270842A (zh) 一次性使用的注射器
US10632261B2 (en) Self-admixing disposable hypodermic needle
CN111032126B (zh) 用于具有较少防腐剂的药物的多次使用药物递送装置
BRPI0415001A (pt) droga contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo
WO2020041447A1 (fr) Aiguille hypodermique jetable à auto-mélange
CN113853227B (zh) 注射装置
US12203865B2 (en) Fluid test device and module
JPH0788184A (ja) 連続液排出装置
JP2019529062A (ja) 自動再構成機能付き自動注射器

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19851897

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3110434

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19851897

Country of ref document: EP

Kind code of ref document: A1